UNIT 12.9 In Vitro Evaluation of Experimental Agents for Anti-HIV Activity

  1. Douglas D. Richman (syncytium formation, PBMC-based assay)1,
  2. Victoria A. Johnson (syncytium formation, PBMC-based assay)2,
  3. Douglas M. Mayers (syncytium formation, PBMC-based assay)3,
  4. Takuma Shirasaka4,
  5. Mary C. O'Brien4,
  6. Hiroaki Mitsuya (CPE assay)4

Published Online: 1 MAY 2001

DOI: 10.1002/0471142735.im1209s08

Current Protocols in Immunology

Current Protocols in Immunology

How to Cite

Richman, D. D., Johnson, V. A., Mayers, D. M., Shirasaka, T., O'Brien, M. C. and Mitsuya, H. 2001. In Vitro Evaluation of Experimental Agents for Anti-HIV Activity. Current Protocols in Immunology. 8:12.9:12.9.1–12.9.21.

Author Information

  1. 1

    University of California, San Diego, La Jolla, California

  2. 2

    University of Alabama at Birmingham, Birmingham, Alabama

  3. 3

    Walter Reed Army Institute of Research, Rockville, Maryland

  4. 4

    National Cancer Institute, Bethesda, Maryland

Publication History

  1. Published Online: 1 MAY 2001
  2. Published Print: DEC 1993


This unit presents an assay that has proven useful as an initial screening test is an HIV cytopathic effect (CPE) inhibition assay in which immortalized T cell lines (e.g., ATH8 or MT2) that are profoundly sensitive to the cytopathic effect of certain strains of HIV are utilized as target cells. Additional protocols assess the anti-HIV activity of certain candidate agents by measuring inhibition of syncytium formation or p24 gag protein production by ELISA. Calculation of the 50% inhibitory concentration (IC50) is also presented.